logo
We Need to Talk About Erectile Dysfunction: 38% of Canadian Men Don't Know You Need a Prescription for ED Medication

We Need to Talk About Erectile Dysfunction: 38% of Canadian Men Don't Know You Need a Prescription for ED Medication

Business Wire5 hours ago

TORONTO--(BUSINESS WIRE)--For Men's Health Week (June 9 to 15), Phoenix, Canada's leading digital health clinic for men, is raising awareness to break the stigma around erectile dysfunction (ED), a medical condition that affects almost half (49.4%) of Canadian men aged 40 to 88.
Thirty-eight per cent of men are unsure or don't think they need a prescription to purchase medication, such as Viagra, for ED.
ED is a medical condition that prevents the ability to get and maintain an erection sufficient for sexual intercourse, with a range of potential causes that could each contribute to the condition, including age, medications, injury, and lifestyle. Despite its prevalence, Phoenix's survey of more than 1,500 Canadians found that there is a significant lack of awareness around ED and its treatment, likely contributing to stigma surrounding the condition.
CANADIANS UNDERESTIMATE THE REACH OF ED
Despite nearly half of Canadian men over 40 being affected, ED's prevalence is underestimated, driving undue stigma. In fact, almost half of Canadians (45%) think that ED affects less than 40 per cent of men 40+. Twenty-seven per cent of Canadians think it affects less than 30 per cent of men 40+.
While Canadians underestimate the prevalence of ED in middle-aged and older men, many are also unaware that the condition can also impact younger men. The survey found that 64 per cent of Canadians don't know that men aged 35 and younger can experience ED. That percentage grows as you look at younger men, with 71% of Canadians unaware that men aged 18 to 25 can be affected. This common misconception can contribute to the stigma around experiencing ED as a younger man, making it more difficult for those struggling to seek care.
'ED is a medical condition that men of all ages can experience. There shouldn't be anything awkward about it, but there is. We're trying to change that," says Kevin Bache, co-founder and co-CEO of Phoenix. "While it may feel uncomfortable, men need to understand what the condition entails, and not shy away from being proactive in discussing it with a doctor. The sooner you get started, the better your chances are at finding mental and physical relief."
WIDESPREAD MISUNDERSTANDING OF ED MEDICATION
Treatment for ED and its underlying cause can vary greatly depending on a patient's prognosis, however, medication is a common and effective treatment. Despite this fact, Phoenix's survey found 18 per cent of men are unsure if ED is treatable with medication, revealing a lack of awareness that may leave many suffering needlessly.
The data also highlighted a concerning gap in awareness that ED medication requires a prescription. Thirty-eight per cent of men are unsure or don't think they need a prescription to purchase medication, such as Viagra, for ED. However, the lack of awareness is most significant among younger Canadians. About three in five Gen Z (59%) don't know that you need a prescription for ED medication: 32 per cent are unsure, and 27 per cent don't think you need a prescription at all.
It is important that Canadians know that ED medication requires a prescription from a medical professional, as they may otherwise be vulnerable to purchasing unauthorized sexual enhancement products sold over the counter, which Health Canada warns could pose serious health risks.
'It's no surprise that people aren't aware of the prevalence of ED – it just doesn't get talked about enough. But the good news is, there are treatment options, and with more openness and awareness, more people can seek support immediately,' says Gavin Thompson, co-founder and co-CEO of Phoenix. 'We built Phoenix to change that. Our mission is simple: make expert care easy to access – fast, discreet, and doctor-led. We're building a future where men take charge of their health with confidence.'
WHAT CANADIANS NEED TO KNOW ABOUT ED
ED can affect men at any age, but it becomes more common as you get older.
ED is more common than you may think, affecting almost half of Canadian men aged 40 to 88.
Many factors can cause ED, including: low levels of testosterone, nervous dysfunction, blood flow complications, medications, medical conditions, lifestyle factors, obesity, diet, drug abuse, smoking, and emotional or psychological complications.
ED is highly treatable, but the first step is consulting a medical professional. Treatment for erectile dysfunction and its underlying cause can vary greatly, making it important to consult a medical professional to receive a diagnosis and devise an effective treatment strategy.
ED medication requires a prescription from a medical professional.
Phoenix is currently available in Ontario, Alberta, British Columbia, Saskatchewan, Manitoba, Nova Scotia, New Brunswick, PEI, and Newfoundland. To learn more about Phoenix's ED support, visit https://www.phoenix.ca/treatments/erectile-dysfunction.
ABOUT PHOENIX
Phoenix is Canada's leading digital health clinic for men, specializing in three areas of treatment – erectile dysfunction, weight loss, and hair loss. The telehealth platform facilitates access to licensed Canadian physicians, treatment options, and free, discreet shipping of prescription medication from coast to coast. Visit Phoenix.ca to learn more.
SURVEY METHODOLOGY
These findings are from a survey conducted by Phoenix from May 20th to May 22nd, 2025, among a representative sample of 1509 online Canadians who are members of the Angus Reid Forum. The survey was conducted in English and French. For comparison purposes only, a probability sample of this size would carry a margin of error of +/-2.53 percentage points, 19 times out of 20.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing

Yahoo

time21 minutes ago

  • Yahoo

GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing

Community Link allows independent pharmacies to direct contract with GoodRx, manage participation in the company's Integrated Savings Program, and access over 90 brand medication partnership offerings Cost-plus pricing is anchored on NADAC Starting July 1, all independent pharmacies will be opted out of GoodRx's Integrated Savings Program by default SANTA MONICA, Calif., June 09, 2025--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of GoodRx Community Link. Designed to address the industry challenges that independent community pharmacies face around complex reimbursement models and competitive pressures, Community Link leverages a cost-plus pricing model based on NADAC to provide predictable pricing and favorable economics. This announcement showcases GoodRx's commitment to helping independent pharmacies better manage pricing while continuing to provide consumers with affordable prices on their medications. "We know independent pharmacies are critical pillars in our communities that help millions of Americans access their medications and they need bespoke solutions to help address the industry problems they face," said Aaron Crittenden, President of Rx Marketplace at GoodRx. "GoodRx Community Link is the result of a multi-year journey to evolve the GoodRx business model and deliver solutions tailored to the specific needs of independent pharmacies. Ultimately, our goal with Community Link is to help improve the retail pharmacy business model and support a bright future for the sector." Community Link enables independent pharmacies to: Direct Contract with GoodRx: Leverages cost-plus pricing anchored on NADAC to provide independent pharmacies with direct control over pricing and favorable margins. A direct contract means the pricing relationship is entirely between GoodRx and the pharmacy, with no PBM involvement. Entering into a direct agreement with GoodRx does not waive a pharmacy's right to participate in ongoing litigation against GoodRx. Manage Participation in GoodRx's Integrated Savings Program (ISP): When a direct contract is signed, independent pharmacies will have the ability to opt-in to ISP as an additional benefit of working with GoodRx. Starting July 1, all independent pharmacies will be opted out of ISP by default. ISP participation may offer more favorable rates than traditional commercial insurance reimbursement. Access Over 90 Brand Medication Deals: A unique offering where the manufacturer buys down the price of a brand medication via GoodRx, making it more affordable for the consumer and economically beneficial for the pharmacy. Examples include Lantus, a Humira® biosimilar, and medical devices such as Dexcom. Starting today, independent pharmacies can use their NCPDP number to login to GoodRx Community Link and manage their relationship with GoodRx: To view a recording of the GoodRx Community Link webinar that was hosted last week, visit: For any questions, please reach out to: communitylink@ About GoodRx GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications. ​GoodRx periodically posts information that may be important to investors on its investor relations website at We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the "SEC") and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release. GoodRx Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated savings, convenience and accessibility; the expected benefits and value of GoodRx Community Link and our Integrated Savings Programs; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. View source version on Contacts Media Contact press@ Sign in to access your portfolio

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance
Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Yahoo

time35 minutes ago

  • Yahoo

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology Enhanced cross-platform compatibility helps simplify device integration, increase longevity of capital equipment, reduce customization development time and lower costs The first of several Phillips Medisize–branded medical connectors planned to launch over the next 18–24 months, TheraVolt™ provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with Phillips Medisize's 60+ years of medical experience HUDSON, Wis., June 09, 2025--(BUSINESS WIRE)--Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of medtech, pharmaceutical drug delivery and in vitro diagnostic devices, announces the launch of TheraVolt™ Medical Connectors. As the first medical connectors launched under the Phillips Medisize brand, TheraVolt is engineered to optimize device integration, functionality, reliability and performance. TheraVolt provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines. Emerging trends in electrophysiology (EP), most notably the rapid adoption of pulsed field ablation (PFA) technology, are driving increased demand for advanced medical connectors that support higher pin count densities and compact design. With enhanced cross-platform compatibility, TheraVolt Medical Connectors help simplify medical device integration, increase longevity of capital equipment, reduce customization development time and lower costs. This can enable more efficient solutions and greater flexibility for medical device companies developing PFA treatment for patients living with atrial fibrillation. "With the launch of TheraVolt, the first of several Phillips Medisize–branded connectors, we are excited to bring deeper collaboration and innovation to complement our exceptional contract design and manufacturing services and proven Molex connectivity solutions to our medtech customers," said Pete Soupir, vice president, MedTech segment at Phillips Medisize. "TheraVolt Medical Connectors empower our medical device customers to develop next-gen EP devices with enhanced integration, connectivity and performance. Their high pin count and high voltage clearance is particularly valuable in medical devices used in electrophysiology treatments, with multiple therapy options, complex functions and expanded data collection." These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with more than 60 years of medical experience from Phillips Medisize. TheraVolt Medical Connectors support next-generation medical device integration and performance through: High Pin Count and Voltage Clearance: Enables the integration of more functionalities, allowing medical device engineers to design multi-therapy medical devices with expanded capabilities, advanced functions and increased data collection. Design Flexibility and Customization: Available off-the-shelf with the flexibility to be tailored to meet diverse application demands, with customizable configurations for specific pin counts and precise electrical requirements. Sterilization Compatibility: Engineered to withstand multiple autoclave cycles, maintaining integrity and performance even under repeated exposure to harsh sterilization processes. Safety and Reliability: Designed to support compliance with IEC and IPC requirements, helping to promote dependable operation in medical applications. Additional Phillips Medisize Medical Connectors are in development and will be delivered over the next 18–24 months. Learn more about TheraVolt Medical Connectors at and About Phillips Medisize Phillips Medisize, a Molex company, collaborates with leading medical technology, pharmaceutical and in vitro diagnostic companies to design, engineer and manufacture lifesaving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to collaborate with customers to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives. For more information, visit About Molex Molex is a global electronics leader committed to making the world a better, more-connected place. With a presence in more than 38 countries, Molex enables transformative technology innovation in the consumer device, aerospace and defense, data center, cloud, telecommunications, transportation, industrial automation, and healthcare industries. Through trusted customer and industry relationships, unrivaled engineering expertise, and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life. For more information, visit View source version on Contacts Media Contact: Merryman CommunicationsHelen Winklerhelen@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance
Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Business Wire

time39 minutes ago

  • Business Wire

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

HUDSON, Wis.--(BUSINESS WIRE)-- Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of medtech, pharmaceutical drug delivery and in vitro diagnostic devices, announces the launch of TheraVolt™ Medical Connectors. As the first medical connectors launched under the Phillips Medisize brand, TheraVolt is engineered to optimize device integration, functionality, reliability and performance. TheraVolt provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines. As the first medical connectors launched under the Phillips Medisize brand, TheraVolt is engineered to optimize device integration, functionality, reliability and performance. Share Emerging trends in electrophysiology (EP), most notably the rapid adoption of pulsed field ablation (PFA) technology, are driving increased demand for advanced medical connectors that support higher pin count densities and compact design. With enhanced cross-platform compatibility, TheraVolt Medical Connectors help simplify medical device integration, increase longevity of capital equipment, reduce customization development time and lower costs. This can enable more efficient solutions and greater flexibility for medical device companies developing PFA treatment for patients living with atrial fibrillation. 'With the launch of TheraVolt, the first of several Phillips Medisize–branded connectors, we are excited to bring deeper collaboration and innovation to complement our exceptional contract design and manufacturing services and proven Molex connectivity solutions to our medtech customers,' said Pete Soupir, vice president, MedTech segment at Phillips Medisize. 'TheraVolt Medical Connectors empower our medical device customers to develop next-gen EP devices with enhanced integration, connectivity and performance. Their high pin count and high voltage clearance is particularly valuable in medical devices used in electrophysiology treatments, with multiple therapy options, complex functions and expanded data collection.' These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with more than 60 years of medical experience from Phillips Medisize. TheraVolt Medical Connectors support next-generation medical device integration and performance through: High Pin Count and Voltage Clearance: Enables the integration of more functionalities, allowing medical device engineers to design multi-therapy medical devices with expanded capabilities, advanced functions and increased data collection. Design Flexibility and Customization: Available off-the-shelf with the flexibility to be tailored to meet diverse application demands, with customizable configurations for specific pin counts and precise electrical requirements. Sterilization Compatibility: Engineered to withstand multiple autoclave cycles, maintaining integrity and performance even under repeated exposure to harsh sterilization processes. Safety and Reliability: Designed to support compliance with IEC and IPC requirements, helping to promote dependable operation in medical applications. Additional Phillips Medisize Medical Connectors are in development and will be delivered over the next 18–24 months. Learn more about TheraVolt Medical Connectors at and About Phillips Medisize Phillips Medisize, a Molex company, collaborates with leading medical technology, pharmaceutical and in vitro diagnostic companies to design, engineer and manufacture lifesaving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to collaborate with customers to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives. For more information, visit About Molex Molex is a global electronics leader committed to making the world a better, more-connected place. With a presence in more than 38 countries, Molex enables transformative technology innovation in the consumer device, aerospace and defense, data center, cloud, telecommunications, transportation, industrial automation, and healthcare industries. Through trusted customer and industry relationships, unrivaled engineering expertise, and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life. For more information, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store